UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

British journal of cancer, 2008-02, Vol.98 (3), p.523-528

2008

Volltextzugriff (PDF)

Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation

Gene therapy, 2011-07, Vol.18 (7), p.702-708

2011

Volltextzugriff (PDF)

T Cell Assays and MIATA: The Essential Minimum for Maximum Impact

Immunity (Cambridge, Mass.), 2012-07, Vol.37 (1), p.1-2

2012

Volltextzugriff (PDF)

Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside

British journal of cancer, 2014-10, Vol.111 (8), p.1469-1475

2014

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Journal of clinical oncology, 2001-07, Vol.19 (13), p.3267-3279

2001

Volltextzugriff (PDF)

Improving the efficacy of cancer immunotherapy

European Journal of Cancer, 2009-05, Vol.45 (8), p.1424-1431

2009

Volltextzugriff (PDF)

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

Cancer Immunology, Immunotherapy, 2008-03, Vol.57 (3), p.303-315

2008

Volltextzugriff (PDF)

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma

Annals of oncology, 2013-04, Vol.24 (4), p.1104-1111

2013

Volltextzugriff (PDF)

The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays

Cancer Immunology, Immunotherapy, 2008-03, Vol.57 (3), p.289-302

2008

Volltextzugriff (PDF)

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond

Cancer Immunology, Immunotherapy, 2011-01, Vol.60 (1), p.15-22

2011

Volltextzugriff (PDF)

Toward the harmonization of immune monitoring in clinical trials: Quo vadis?

Cancer Immunology, Immunotherapy, 2008-03, Vol.57 (3), p.285-288

2008

Volltextzugriff (PDF)

Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program

Cancer Immunology, Immunotherapy, 2010-04, Vol.59 (4), p.619-627

2010

Volltextzugriff (PDF)

526 A Phase I study of the dual, intravenous (IV) phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 in combination with irinotecan in patients (pts) with colorectal cancer (CRC) and other advanced solid tumors

European journal of cancer (1990), 2014-11, Vol.50, p.171-171

2014

Volltextzugriff (PDF)

Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells

Cancer Immunology, Immunotherapy, 2010-04, Vol.59 (4), p.609-618

2010

Volltextzugriff (PDF)

366 Phase I Dose-escalation Study of the Oral Dual MTOR/PI3K Inhibitor BEZ235, Solid Dispersion System (SDS) Sachet Formulation, in Patients with Advanced Solid Tumors

European journal of cancer (1990), 2012-11, Vol.48, p.112-112

2012

Volltextzugriff (PDF)

Common variants of the TCF7L2 gene are associated with increased risk of type 2 diabetes mellitus in a UK-resident South Asian population

BMC medical genetics, 2008-02, Vol.9 (1), p.8-8

2008

Volltextzugriff (PDF)

The promoter polymorphism -232C/G of the PCK1 gene is associated with type 2 diabetes in a UK-resident South Asian population

BMC medical genetics, 2009-09, Vol.10 (1), p.83-83, Article 83

2009

Volltextzugriff (PDF)

358 A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTOR Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer

European journal of cancer (1990), 2012-11, Vol.48, p.109-109

2012

Volltextzugriff (PDF)

Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2

Cancer Immunology, Immunotherapy, 2006-03, Vol.55 (3), p.246-253

2006

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of the Mitochondrial-specific Rhodacyanine Dye Analog MKT 077

Clinical cancer research, 2000-01, Vol.6 (1), p.42-49

2000

Volltextzugriff (PDF)

Preoperative autologous blood donation for bone marrow harvests: Are we wasting donors' time and blood?

Transfusion medicine (Oxford, England), 2006-02, Vol.16 (1), p.57-62

2006

Volltextzugriff (PDF)

1001MO Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR bispecific, in phase I dose escalation

Annals of oncology, 2024-09, Vol.35, p.S681-S682

2024

Volltextzugriff (PDF)

Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

Clinical cancer research, 2012-04, Vol.18 (8), p.2290-2300

2012

Volltextzugriff (PDF)

A Phase I and Pharmacological Study of the Farnesyl Protein Transferase Inhibitor L-778,123 in Patients with Solid Malignancies

Clinical cancer research, 2001-12, Vol.7 (12), p.3894-3903

2001

Volltextzugriff (PDF)

Sorafenib in Advanced Hepatocellular Carcinoma

The New England journal of medicine, 2008-07, Vol.359 (4), p.378-390

2008

Volltextzugriff (PDF)

1 – 25 von 705

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(599)
Mit Volltextzugriff
(570)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(377)
Life Sciences & Biomedicine
(266)
Humans
(217)
Biological And Medical Sciences
(130)
Female
(119)
Male
(108)
Physical Sciences
(91)
Medical Sciences
(88)
Animals
(86)
Adult
(79)
Middle Aged
(77)
Aged
(68)
Oncology
(53)
Chemistry
(47)
Fundamental And Applied Biological Sciences. Psychology
(47)
Physics
(43)
Pharmacology. Drug Treatments
(42)
Exact Sciences And Technology
(35)
General & Internal Medicine
(32)
Antineoplastic Agents
(30)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation

T Cell Assays and MIATA: The Essential Minimum for Maximum Impact

Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Improving the efficacy of cancer immunotherapy

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma

The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond

Toward the harmonization of immune monitoring in clinical trials: Quo vadis?

Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program

526 A Phase I study of the dual, intravenous (IV) phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 in combination with irinotecan in patients (pts) with colorectal cancer (CRC) and other advanced solid tumors

Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells

366 Phase I Dose-escalation Study of the Oral Dual MTOR/PI3K Inhibitor BEZ235, Solid Dispersion System (SDS) Sachet Formulation, in Patients with Advanced Solid Tumors

Common variants of the TCF7L2 gene are associated with increased risk of type 2 diabetes mellitus in a UK-resident South Asian population

The promoter polymorphism -232C/G of the PCK1 gene is associated with type 2 diabetes in a UK-resident South Asian population

358 A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTOR Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer

Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2

A Phase I and Pharmacokinetic Study of the Mitochondrial-specific Rhodacyanine Dye Analog MKT 077

Preoperative autologous blood donation for bone marrow harvests: Are we wasting donors' time and blood?

1001MO Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR bispecific, in phase I dose escalation

Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

A Phase I and Pharmacological Study of the Farnesyl Protein Transferase Inhibitor L-778,123 in Patients with Solid Malignancies

Sorafenib in Advanced Hepatocellular Carcinoma

Suchergebnisse filtern